Zacks Investment Research upgraded shares of ContraFect Corp (CFRX) from N/A to OUTPERFORM on January 26, 2015, with a target price of $10.00.
CFRX is a clinical stage biotech company focused on the discovery and development of proteins and antibodies for infectious diseases. The company's two platforms: lysins and monoclonal antibody target conserved regions of bacteria or viruses, and therefore have the potential to address multi-drug resistance. CFRX's lead lysin candidate CF-301 will enter into Phase I in 1Q15 for the treatment of Staph bloodstream infections including infective endocarditis, caused by MSSA and MRSA. Its second lead candidate, CF-404, is a universal treatment for influenza, and is expected to enter into clinic in 2016. We are optimistic about CFRX's prospect and rating its shares Outperform.
To get a free copy of the research report on ContraFect Corp (CFRX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment